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Community acquired bacterial meningitis in adults – mobile summary 
Bacterial meningitis in adults carries a significant morbidity and mortality. In many parts of the world 
the most common pathogen is Streptococcus pneumoniae, which tends to occur at an older age 
whereas Neisseria meningitidis generally occurs in younger adults. Staphylococcus aureus, the 
Enterobacteriaceae, Streptococcus suis and Listeria monocytogenes are also prominent pathogens in 
different parts of the world or specific populations. Widespread use of conjugate vaccines against 
Haemophilus influenzae type B, certain serotypes of Streptococcus pneumoniae and Neisseria 
meningitidis has reduced the incidence of bacterial meningitis although mostly in children. Herd 
immunity has provided some benefits for adults but serotype replacement may undermine any 
benefits seen in older populations.  In meningococcal disease, different serogroups are also 
emerging in areas where they had been previously unrecorded.  
The mortality from bacterial meningitis is high and significant for pneumococcal disease, in part due 
to the uncontrolled host inflammatory response. Although much is still unknown, new discoveries in 
pathogenesis give an improved understanding of colonisation and invasion into the blood stream 
and central nervous system, as well as factors responsible for immune system evasion. This in turn 
allows new targets for vaccines and therapeutics to be developed.  
Clinical diagnosis, based on symptoms and signs, is difficult and cerebrospinal fluid analysis is 
essential both to confirm the aetiology and to perform antimicrobial susceptibility testing of any 
organism isolated. Newer molecular techniques are useful for diagnosis if culture is negative.  The 
role of neuroimaging before lumbar puncture is controversial, and is only recommended in cases 
where clinical features suggest there may be brain shift.  
Early antibiotic treatment saves lives and empirical antibiotics should be tailored to local resistance 
patterns. In general, beta-lactams should be a component of empirical therapy where possible. 
Adjunctive corticosteroids should be given in some circumstances. Further research should focus on 
epidemiological surveillance, developing new vaccines and new adjunctive therapies.  
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Abstract 
Over the last several decades, there has been a reduction in the incidence of bacterial meningitis in 
children but there remains a significant burden of disease in adults, carrying a mortality of up to 
30%. Although the pathogenesis of bacterial meningitis is not completely understood, our 
knowledge of bacterial invasion and entry into the central nervous system is improving. Clinical 
features alone cannot determine whether meningitis is present and cerebrospinal fluid analysis is 
essential for diagnosis. Newer technologies, such as multiplex polymerase chain reaction, and novel 
diagnostic platforms that incorporate proteomics and genetic sequencing, may help provide a 
quicker and more accurate diagnosis. Even with appropriate antimicrobial therapy, mortality is high 
and so attention has focused on adjunctive therapies; adjunctive corticosteroids are beneficial in 
certain circumstances. Any further improvements in outcome are likely to come from either 
modulation of the host response or novel approaches to therapy, rather than new antibiotics. 
Ultimately the best hope to reduce the disease burden is with broadly protective vaccines.  
 
Search Strategy 
We searched SCOPUS with the terms “Meningitis”,“meningo*”,“neurological infection” together 
with “Aetiology”,“epidemiology”,“treatment”,“management”,“antibiotic”, “antimicrobial”, 
“investigation”, “therapy”, “prevention”, “vaccin*”,“lumbar puncture” for articles published 
between 1st January 2010 and 31st Dec 2015. We also included any studies referenced within these 
articles if deemed relevant. In addition, any older references known to the authors were also 
included, as were abstracts of articles not written in English. Review articles are included to guide 
the reader to a more extensive reference list. 
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Burden of disease and epidemiology  
The incidence of bacterial meningitis varies throughout the world. In Western settings, the incidence 
is 1-2 cases per 100,000, whereas it can reach 1,000 cases per 100,000 in the Sahel region of Africa 
(Figure 1)1-3.   A huge reduction in incidence has been seen over the last few decades, largely 
secondary to the introduction and widespread use of conjugate vaccines1,3-6. Conjugate vaccines 
have a protein attached to purified bacterial capsular polysaccharide. This elicits a more robust and 
sustained immune response, especially in young children. Table 1 gives an overview of vaccines 
currently available to prevent bacterial meningitis. Much of the reduction in incidence has been in 
children under one year1,5.  Similarly the largest reductions in meningitis-associated mortality, 
globally, have been seen in children under five years of age, with a 43% decrease in neonates and a 
54% reduction in children aged between one and 59 months7.   For those over five years, the 
reported number of deaths globally only reduced by 2·7%, from 165,900 to 161,500 between 1990 
and 20137.  
Streptococcus pneumoniae  
Pneumococcus is the commonest cause of bacterial meningitis in adults in much of the world1,5,8,9. 
There are over 90 antigenically different serotypes of S. pneumoniae as determined by the 
polysaccharide capsule - the target for all currently licensed vaccines. 
Pneumococcal conjugate vaccines (PCV) have been used for the last 15 years.  PCV7 targeted seven 
pneumococcal serotypes and more recently PCV10 and PCV13 (covering ten and thirteen serotypes 
respectively) were licensed in the US and Europe.   The polysaccharide vaccine, PPV23, covers 23 
serotypes.  Until recently, conjugate vaccines were largely used only in children but a recent 
placebo-controlled trial in people 65 years of age and older has shown good efficacy of PCV13 in 
preventing vaccine-type pneumococcal pneumonia, non-bacteraemic pneumonia and invasive 
pneumococcal disease, with vaccine efficacies of 45·6%, 45%, and 75% respectively10. Although the 
5 
 
majority of studies on the immunogenicity of pneumococcal vaccines are non-comparative, there is 
some evidence that PCV is more immunogenic11. The conjugate vaccines also produce substantial 
herd immunity, when vaccination of part of the population provides protection for non-vaccinated 
individuals. . Recent large studies have shown dramatic reductions of disease caused by vaccine 
serotypes in both vaccinated and unvaccinated populations12-15. 
Since conjugate vaccines were first introduced serotype replacement has been observed. This is an 
increase in the incidence of disease and/or asymptomatic carriage caused by non-vaccine 
serotypes.16-19  Despite this the overall incidence of invasive pneumococcal disease has dropped.  A 
meta-analysis from Europe, the Americas and Australia  confirmed a sustained reduction in the 
incidence of pneumococcal meningitis in children seven years post-vaccination (risk ratio for 
meningitis was 0·40, (95% CI 0·25-0·64). There was a similar, but smaller, reduction in adults with a 
relative risk of meningitis in 18-49 year olds of 0·61, (95% CI 0·4-0·95) seven years after vaccination. 
For older adults aged 50-64 years, there was a decrease in meningitis caused by the vaccine 
serotypes but this was offset by a significant increase in non-vaccine serotype disease (RR 2·83 95% 
CI 1·46-5·47)20. Mathematical models have predicted a substantial reduction in disease following the 
introduction of PCV13, even taking serotype replacement into account 21,22.  Recent observational 
studies confirm this with a 32% reduction in invasive pneumococcal disease following the 
introduction of PCV13, but a 25% increase in non-PCV13 serotypes23. 
Neisseria meningitidis 
Meningococci are categorised into 13 serogroups; five (A, B, C, W135, and Y) are responsible for 
most cases of invasive disease. Serogroup B is the commonest strain across Europe, including 
England and Wales where it is responsible for the majority of cases24,25. Serogroup Y is predominant 
in the USA26 and the second most common in parts of Europe 27. Recently there has been a rise in 
serogroup W135  in the UK, which has been shown to be linked with a South American clone. 
Disease caused by this clone is associated with a higher mortality as they are part of the more deadly 
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ST11 clonal complex (or cc11)28.  The same clonal complex is responsible for recent outbreaks of 
meningococcal C disease amongst gay men29,30.  
Serogroup C was previously responsible for most meningococcal disease in Western countries, but 
incidence has markedly declined following the introduction of the meningococcal C conjugate 
vaccine. In the Netherlands, incidence has declined from 4·5/100,000 in 2001 to 0·6/100,000 in 
201227. Similar results have been seen in other countries5,14. In 2015, serogroup C disease appeared 
for the first time in the Sahel region of Africa31. Serogroup A has been responsible for large 
outbreaks in the meningitis belt of Africa; however, massive reductions have been seen in recent 
years following widespread vaccination 32,33. The Meningitis Vaccine Project – a collaboration 
between the World Health Organisation and PATH (the Programme for Applied Technology in 
Health) - set out to vaccinate 250 million people in Africa with the new serogroup A conjugate 
vaccine. This has been a massive public health triumph. In Burkina Faso there was a risk reduction of 
99.8%  and similar dramatic results were seen in Niger where serogroup A disease had virtually 
disappeared by 201133, 34. Meningococcal A is also responsible for epidemics in parts of Asia including 
India, Indonesia, Nepal, Mongolia, and Pakistan35.  
Other bacteria 
Haemophilus influenzae type B was a significant cause of meningitis, especially  in infants and young 
children, prior to widespread use of conjugate vaccines6 . As with meningococcal disease, H. 
influenzae type B has virtually disappeared in areas where immunisation has been implemented, but 
remains a problem where vaccination is not commonplace36. The incidence of invasive haemophilus 
disease due to non-type B strains has, however, increased in recent years.  The majority of these 
cases are due to non-typeable organisms but a number are due to other encapsulated forms of H. 
influenzae, in particular types e and f 37-39.   
Streptococcus suis is a major cause of meningitis in some parts of Asia, especially Thailand and 
Vietnam. It is a pathogen of pigs, and close contact with pigs or pork is a significant risk factor for 
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disease. Although the case fatality rate is only 4%, some degree of hearing loss occurred in more 
than 50% of survivors 40. It has also been reported from many other parts of the world41-43. Other 
causes of meningitis include the Enterobacteriaceae, Staphylococcus aureus1,5, and Listeria 
monocytogenes which  is normally seen in those with risk factors such as older adults, alcoholics, 
diabetics, patients with malignancies, and those on immunosuppressive drugs4,44-47.  
Pathogenesis  
Many aspects of the pathogenesis of bacterial meningitis have yet to be understood; however, there 
are four main processes: colonisation, invasion into the blood stream, survival in the bloodstream 
and, entry into the subarachnoid space. The subsequent inflammation and neurological damage is 
caused by a combination of bacterial and host factors.  Figure 2 schematically shows the 
pathogenesis of S. pneumoniae and N. meningitidis meningitis.  
Colonisation  
Many bacteria that cause meningitis initially colonise the mucous membranes of the upper 
respiratory tract. Colonisation involves a combination of the bacteria adhering to the cell surfaces 
and avoidance of the host’s defence mechanisms. Many organisms have fimbriae (a fringe) or pili 
(hair-like appendages) which assist in their attachment to the epithelium.  The main requirement for 
meningococcal adhesion is the type IV pili (tfp).  Tfp adhere via various receptors including the 
platelet activating factor receptor (PAFR), beta 2 adrenoceptor receptors and CD14764, 65. The 
meningococcal outer membrane proteins including lipopolysaccharide and the opacity proteins (OpC 
and OpA) have also been proposed to contribute to the maintenance of adhesion 48,49. Three main 
receptors have been proposed for pneumococcal adhesion to epithelial surfaces – PAFR, laminin 
receptors and the polyimmunoglobulin receptor (PIgR).  
Invasion  
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Invasion into the blood stream occurs either transcellularly (passing through the cells) or 
pericellularly (between cells) 85. Pneumococci utilise both of these methods via receptors such as the 
PAFR or the pneumococcal choline binding receptor50.  Meningococci are transported across the 
epithelial cells in phagocytic vacuoles51. Survival in the bloodstream requires evasion of the immune 
system. Meningococci utilise factor H binding protein (fHbp), a lipoprotein responsible for 
dysregulation of the complement pathway and Por A, an outer membrane protein, to evade 
complement52,53.  
Most cases of meningitis probably occur following bacteraemia but the high incidence of 
pneumococcal meningitis in patients with sinusitis and otitis media suggest direct spread to the 
central nervous system may also occur 8.  This possibility is supported by mouse models showing 
pneumococcal meningitis after respiratory infection without blood stream involvement 54.  Direct 
entry from the nose through dural defects is also possible. 
Entry into the central nervous system and inflammation 
Due to a lack of host defences in the subarachnoid space, bacteria multiply relatively unhindered. 
Bacterial components are recognised by pattern recognition receptors, present on microglia and 
other brain cells. A cascade of events is then triggered that ultimately leads to the release of pro-
inflammatory mediators such as TNF, IL-6 and IL-1β. Many of these are released in greater quantity 
in pneumococcal disease compared with other organisms and may account for the worse prognosis 
associated with pneumococcal meningitis55. Following the release of the  cytokines granulocytes 
cross the blood-brain barrier and it becomes more permeable.  Bacterial lysis occurs in response to 
antibiotics or, in the case of pneumococci, when the bacteria reach the stationary growth phase 
(autolysis). Lysis leads to the release of pro-inflammatory agents, such as lipopolysaccharide, 
lipotechoic acid and peptidoglycans, from the cell wall of the bacterium and augments the 
inflammatory process56.   
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Neutrophils have been implicated in much of the neurological damage found in meningitis and MRP-
14, a protein expressed in myeloid cells, has been found in the CSF of patients with pneumococcal 
meningitis; inhibition of MRP-14 led to reduced sequelae in a mouse model57. Matrix 
metalloproteinases (MMPs) are released by white cells in the CSF. They are seen very early in 
infection and aid the release and activation of pro-inflammatory cytokines, the degradation of 
extracellular matrix components, and the recruitment of further leukocytes into the subarachnoid 
space. As with other inflammatory mediators, the levels of MMP-9 are especially high in 
pneumococcal meningitis55.  
Genetic predisposition 
 
Several studies have suggested a genetic predisposition to bacterial meningitis, with most related to 
deficiencies that affect the complement system. In particular, C2 deficiency was found in 58% of 
patients with pneumococcal meningitis, factor D deficiency predisposed to meningococcal disease, 
and susceptibility to meningococcal serogroups W135 and Y arose in those with properdin 
deficiency. Case-control studies revealed that polymorphisms in mannose binding lectin and 
complement factor h (cfh) were associated with susceptibility to pneumococcal and meningococcal 
disease, respectively. Approximately one fifth of patients with meningococcal disease were defined 
as having meningitis. Due to variations in definitions no analysis could be performed excluding 
patients who did not have meningitis58.  More recently genome wide association studies have 
confirmed that a polymorphism in cfh predisposes to meningococcal disease, just over one third had 
meningitis,  and a polymorphism in the C3 gene predisposes to pneumococcal meningitis59,60.  
Diagnosis 
Clinical diagnosis 
Diagnosing bacterial meningitis clinically can be difficult as many illnesses present with similar 
symptoms. The classical triad of neck stiffness, fever and altered consciousness is seen in less than 
50% of patients with acute bacterial meningitis8. However, any two of headache, fever, neck 
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stiffness and altered consciousness are seen much more commonly, in up to 95%8. Kernig’s and 
Brudzinski’s signs have been used in the clinical assessment of meningitis for many years, but their 
usefulness is doubtful. They have been reported to have high specificity (up to 95%), although this is 
very clinician dependent, but the sensitivity can be as low as 5%61. They should not be relied upon to 
exclude, or establish, a diagnosis of bacterial meningitis.  Differential diagnoses include viral 
meningitis and other forms of infective meningitis, non-infectious causes of meningitis such as 
autoimmune conditions, medications such as trimethoprim and non-steroidal anti-inflammatories 
and malignancy, as well as non-meningitic illnesses such as sub-arachnoid haemorrhage, migraine 
and other ‘simple’ viral illnesses.  
Laboratory diagnosis 
The gold standard for diagnosing meningitis is examination of the cerebrospinal fluid (CSF); typical 
findings are shown in table 2. Measuring the opening pressure at the time of lumbar puncture (LP) is 
very useful and is often high in bacterial meningitis. A raised white blood count in the CSF is taken as 
an indication of inflammation of the meninges, although some patients may have bacteria in their 
CSF without an elevated white blood count. These patients have a poor prognosis. 
CSF protein and glucose should also be measured. Patients with bacterial meningitis typically have a 
raised protein and low glucose. CSF glucose is influenced by the serum glucose concentration and, 
therefore, a concurrent serum sample must also be taken. CSF lactate may have advantages over 
CSF glucose in that it is unaffected by the serum concentration. CSF lactate, if taken prior to 
antibiotics, has a sensitivity of 0·93 (95% CI 0·89-0·96) and specificity of 0·96 (CI 0·93-0·98) in 
differentiating bacterial from viral meningitis62. Serum and CSF procalcitonin concentrations have 
also been suggested as useful tests to indicate a likely bacterial cause but well-designed diagnostic 
accuracy studies, including cost-effectiveness analyses, are required before recommending the 
routine use of procalcitonin in the diagnostic workup of bacterial meningitis. 
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Gram stain and culture of the CSF allow both the identification of the causative pathogen and 
assessment of antimicrobial susceptibilities.  If the LP is delayed until after antibiotics have been 
given, the likelihood of identifying an organism may be reduced by up to 44%63,64. Molecular 
methods are, therefore, becoming increasingly important for diagnosis. The most common of these 
is the polymerase chain reaction (PCR) which can detect organisms in blood or CSF for several days 
after antibiotics have been given 65,66. It  has high sensitivity (87-100%) and specificity (98-100%) 67-70.  
Dried spot CSF PCR tests, which could be useful In the absence of a laboratory, have shown a 90% 
sensitivity in diagnosing bacterial meningitis caused by S. pneumoniae, S. suis, and N. meningitidis 71.  
In addition to CSF analysis, blood cultures may identify the cause and should be taken before 
antibiotics are given.  
There has been recent interest in the ability to detect multiple pathogens with one platform such as 
multiplex PCR, 16S PCR, MALDI-TOF (matrix associated laser dissociation and ionisation-time of 
flight), and whole genome sequencing72 73. The 16S rRNA gene is present in almost all bacteria; one 
meta-analysis showed 16S rRNA PCR to be both sensitive and specific for the diagnosis of bacterial 
meningitis compared with standard culture (pooled sensitivity of 92% and specificity of 94%)74. The 
commonest method for species identification was sequencing. MALDI-TOF is now commonplace in 
many clinical laboratories. It utilises the protein mass of the organism to identify the bacteria. This 
has revolutionised clinical microbiology by reducing the time to identification of an organism; it 
normally requires a cultured organism but there are reports of success direct from CSF 75. Whole 
genome sequencing has been used in the investigation of outbreaks, but as it becomes faster and 
cheaper, it may be incorporated into routine surveillance and diagnosis76,77.   
Loop-mediated isothermal amplification (LAMP) is another method of DNA amplification and 
detection. The LAMP method is quick, with results in less than 2 hours, and a positive result can be 
seen with the naked eye.  This technique has recently shown good sensitivity for detection of N. 
meningitidis, S. pneumoniae, H. influenzae and Mycobacterium tuberculosis 78-81 . It has also recently 
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been evaluated as a bedside test in the UK where it had a PPV of 100% and a NPV of 97%82. The 
speed and ease of diagnosis makes this a very attractive diagnostic tool, especially within resource 
poor settings. 
The role of neuroimaging   
The use of neuroimaging before LP has generated considerable debate with some recommending 
cerebral imaging is performed before LP for all patients. However this has been associated with 
delays in antibiotic administration, reduced likelihood of identifying a pathogen and an increase in 
mortality64,83-85.  The reason for neuroimaging is to detect cerebral herniation syndromes, or shift of 
brain compartments. If these are present and an LP is performed, there is the theoretical concern 
that a reduction in pressure caused by the LP can precipitate a further brain shift which may lead to 
fatal herniation. Neuroimaging should therefore be performed on patients who have clinical signs 
which may suggest brain shift and, if shift of brain compartments or herniation is found, LP should 
be delayed. Indications that brain shift might be present include focal neurological signs and reduced 
level of consciousness. The exact level of consciousness at which an LP is safe is debated and 
different authorities recommend different cut-off points ranging between 8 and 13 on the Glasgow 
coma scale 86-88. 
No study has identified features associated with an increased risk of herniation post-LP. One study 
found certain features (age over 60 years, immunocompromise, history of neurological disease, 
recent seizure, and  certain abnormal neurological examination findings) were associated with 
abnormalities on imaging, but the risk of herniation or brain shift was not assessed84.   A recent 
retrospective study found that removing impaired mental status as a contraindication for LP was 
associated with significantly earlier treatment and a favourable outcome however there are several 
limitations to this study and cause and effect cannot be attributed89. Every patient with suspected 
bacterial meningitis must be carefully assessed to ascertain whether they have signs or symptoms 
consistent with brain shift. If they do not, LP should be carried out as soon as possible without prior 
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neuroimaging The supplementary table  outlines the situations when neuroimaging should be 
performed before LP. 
Treatment 
Antibiotics should be given as soon as possible to patients with suspected bacterial meningitis, 
ideally after both blood and CSF have been obtained for culture. Early antibiotic treatment is 
associated with a lower mortality83. If there are delays in sampling, the priority is for treatment to be 
given. Many antibiotic regimens are based on data from animal models or clinical experience rather 
than randomised trials. The choice of antibiotic depends on the likely pathogen, local patterns of 
antibiotic resistance and the CSF penetration of the drug. Penicillin and other beta-lactams are 
effective against the  commonest pathogens and the CSF concentration (even with uninflamed 
meninges) tends to be close to the minimum inhibitory concentrations for moderately susceptible 
bacteria90. The worldwide emergence of antimicrobial resistance, especially against S. pneumoniae, 
affects the choice of empirical treatment in many countries. This is especially important in the 
poorer regions of the world where newer antibiotics may not be available or affordable. Table 3 
gives recommendations for empirical antibiotics. 
Antimicrobial resistance 
Penicillin-resistant pneumococci have been reported from all parts of the world91 and have been 
associated with an increase in mortality92. Vancomycin is widely recommended when penicillin-
resistant pneumococci are possible, but due to the fact that it crosses the blood brain barrier poorly 
it should be used in conjunction with another antimicrobial, often a cephalosporin.  .  
Fluoroquinolones may be good alternatives in the era of penicillin-resistant pneumococci. 
Experimental mouse models have shown moxifloxacin to be equivalent to cephalosporins93. Caution 
should be exercised in using fluoroquinolones as single agents as organisms may rapidly develop 
resistance and clinical data are lacking. There are several case reports and case series showing the 
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efficacy of other antibiotics in meningitis, such as ceftaroline94,  linezolid95,96, daptomycin97-99, and  
doripenem100. Without evidence from comparative therapeutic trials, these agents should be used 
with caution and only when other better tested agents cannot be used either because of resistance, 
patient intolerance or allergy.  
Efforts should be made to identify local patterns of antibiotic resistance to determine the optimal 
empirical treatment for each geographic area. In the UK, where there is a low prevalence of 
penicillin-resistance, third-generation cephalosporins (cefotaxime or ceftriaxone) remain the 
empirical choice. However, many parts of the world have penicillin-resistant pneumococci (MIC 
≥0·12µg/ml) with rates of approximately 25% in  the United States and parts of Europe (e.g. Spain, 
Croatia, Romania) and over 50% in Asia; 100% of isolates were found to be penicillin resistant in 
Vietnam and Thailand but numbers were small (n=6 and 1 respectively)101-103. In these areas 
vancomycin (with or without rifampicin) should be given in addition to a third-generation 
cephalosporin 104. Alternatives are listed in table 3. 
Antibiotic resistance in meningococci is rare27 although decreased susceptibility to penicillin has 
been particularly associated with some serogroups, especially C and W135105-108.  
Duration of therapy 
There is limited trial evidence to guide how long to treat adults with bacterial meningitis. Using 
shorter courses of antibiotics can reduce hospital stay and costs and may also reduce the risk of 
adverse events such as nosocomial infections. Paediatric studies have shown that shorter courses 
are safe and effective 109,110. A meta-analysis, looking at all causes of bacterial meningitis in children, 
found a short (4-7 days) course to be as efficacious as a long (7-14 days) course of antibiotics; 
unfortunately, no adult studies could be identified for inclusion111. Three days of intravenous 
benzylpenicillin has been shown to be sufficient for adults with meningococcal disease112;  there was 
no control group in this study, but the mortality of 9% is in keeping with other studies8,25,113. During 
meningococcal epidemics, a single dose of ceftriaxone or chloramphenicol is effective109.  
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Although there are no randomised trials, current guidance in many richer nations is to give relatively 
short courses of antibiotics for meningococcal disease ( 5 to 7 days ), and a slightly longer duration in 
pneumococcal meningitis (10-14 days)114 115. Listeria meningitis should be treated for a minimum of 
21 days.  
Adjunctive therapies 
Even in the presence of a susceptible organism and appropriate antibiotics, mortality in bacterial 
meningitis is high, around 10-30% in industrialised nations 4,8,113,116-119 and nearer 50% in many 
poorer nations 120-122  .The high number of deaths, despite apparently appropriate treatment,  is 
thought to be due to the inflammatory processes described earlier. Efforts have, therefore, focused 
on identifying useful adjunctive therapies which might reduce inflammation and brain oedema.   
Corticosteroids 
Following several paediatric studies123 , a large multi-centre European randomised controlled trial in 
adults showed a significant reduction of both an unfavourable outcome and death in patients who 
were treated with dexamethasone compared to placebo (RR 0·59 and 0·48 for unfavourable 
outcome and death respectively), most striking for the subgroup of patients with pneumococcal 
meningitis124. Subsequent studies carried out in adults in Malawi and Vietnam failed to reproduce 
the European findings122,125, although there was a better outcome (significant reduction in the risk of 
death at 1 month and risk for death or disability at 6 months) for patients in Vietnam with confirmed 
bacterial meningitis. A meta-analysis of individual patient data (n=2029) suggested the differences 
were not due to the high rates of HIV and tuberculosis in these countries126. This meta-analysis 
concluded that there were no subgroups that might benefit from adjunctive dexamethasone, 
although post-hoc analyses did suggest there might be some benefit in HIV negative adults and a 
lower rate of hearing loss amongst all survivors.  
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Another meta-analysis  of 25 studies, in both adults and children, showed a small reduction in 
hearing loss in adults treated with corticosteroids compared with placebo (16% versus 22% RR 0·74, 
95%CI 0·56-0·98) but no difference in mortality152. A subgroup analysis demonstrated a slight decline 
in mortality in all patients with pneumococcal meningitis (RR 0·84 95% CI 0·72-0·98) with no effect 
on H. influenzae or meningococcal meningitis (although numbers in these groups were very small).  
It should be noted that this benefit did not remain when a random-effects model was used (which 
may have been more appropriate given the heterogeneity of the studies (I2 47%))123. 
Both these meta-analyses compared very diverse studies and populations including children and 
adults, high and low socio-economic status and differences in co-morbidities. This is reflected in the 
heterogeneity of the analyses and possibly accounts for the conflicting conclusions. However, there 
needs to be a balance between the risks and potential benefits of corticosteroid use. Overall, it 
seems that corticosteroids may offer a small benefit in adults with regard to reducing hearing loss 
and may have a slightly lower mortality in pneumococcal meningitis. In most studies there is no 
increase in side-effects when corticosteroids were given in comparison to placebo. It is, therefore, 
recommended to give steroids to all adults with suspected bacterial meningitis in resource rich 
countries. Although the meta-analyses did not demonstrate a difference between countries of high 
and low income, there was considerable heterogeneity and in lower income countries the benefits 
are probably less pronounced; therefore, corticosteroids are not recommended in this group.  
The dose of corticosteroids differs between trials, but the one that was used in the large Dutch trial 
is 10 mg of dexamethasone given four times a day124. The Cochrane review and expert guidelines 
recommend administration with or just prior to the first antimicrobial dose150. Sub-group analyses in 
both meta-analyses showed no statistical differences in terms of mortality when corticosteroids 
were given before or with antibiotics compared with when they were given afterwards123,126. There 
were differences when hearing loss was the outcome of interest and indeed the effect size was 
bigger in the group who received corticosteroids after antibiotics compared with the group who 
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received corticosteroids before or concurrently (RR 0.62 (95% CI 0.43-0.89) versus RR 0.8 (95% CI 
0.7-0.92))123.  
Other adjunctive therapies  
Glycerol and hypothermia have been trialled as potential adjunctive therapies in bacterial 
meningitis. Theoretically osmotic substances such as glycerol can draw extravascular fluid from the 
brain into the vascular space and reduce intracranial pressure. One clinical study in adults, 
conducted in a resource limited setting with a high HIV prevalence,  failed to show any benefit120. 
Induced hypothermia is used as a treatment for cerebral hypoxaemia following cardiac arrest and 
animal models have shown it to reduce intracranial hypertension in meningitis. Observational clinical 
studies also suggested it might be beneficial 127,128. However, a recent randomised controlled trial 
was stopped early due to an increased risk of death in patients in the intervention arm 129. It is 
unlikely that hypothermia or glycerol will be widely implemented without adaptation and further 
controlled trials. 
Prognosis and sequelae 
 
Features associated with a poor prognosis include older age, reduced conscious level, tachycardia, a 
CSF leukocyte count of less than 1000 x 109 cells/ml, reduced platelet count8. Prognosis may be 
improved by instigating both antibiotic and steroid treatment early3. Sequelae are more common in 
pneumococcal meningitis than meningococcal meningitis. Hearing loss is a one of the most common 
problems after meningitis, particularly pneumococcal meningitis, and a prompt hearing assessment 
with cochlear implants can be incredibly beneficial for the patient.  Other sequelae include limb loss, 
especially if meningococcal sepsis is present, subdural empyema, hydrocephalus and seizures. Other 
less life threatening sequelae include neurocognitive dysfunction including sleep disorders.  
The Future  
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New vaccines 
Many of the pneumococcal vaccines in development are focussing on protein-based strategies 
(rather than being based on the capsular polysaccharide), to be given either in addition or as a 
replacement to conjugate vaccines. This may allow pan-serotype protection and eliminate the 
problem of serotype replacement. Several early phase studies have been conducted, one of which 
(combining pneumolysin toxoid and histidine triad protein D, a pneumococcal surface protein 
thought to be involved in complement inhibition) has recently reported good evidence of 
immunogenicity with an acceptable safety profile in both younger and older adult cohorts130-132.  
The search for a widely effective vaccine against meningococcal serogroup B has been difficult 
because of the poorly immunogenic capsule. Vaccines were developed that targeted sub-capsular 
proteins (see figure 3) and were used with some success in epidemics in Norway, Cuba, Brazil, New 
Zealand, and France133-135. However, they were poorly immunogenic in young children and strain 
specific, and so could not be rolled out on a larger scale. Using a novel genome sequencing method, 
a multicomponent serogroup B meningococcal vaccine has been produced. It contains four 
immunogenic components: 3 proteins – neisserial adhesion A (NadA) which is involved in the 
adhesion of Neisseria to the nasal epithelium, neisserial heparin binding antigen (NHBA) thought to 
be involved in serum resistance, and fHbp - in combination with outer membrane vesicles from the 
New Zealand vaccine strain. The vaccine has been shown to be immunogenic in young infants136,137 
and older children138 . It may also reduce carriage rates of other meningococcal serogroups (as some 
of the sub-capsular antigens in the vaccine are also present in non-B serogroups)139, indicating that it 
could affect transmission once fully implemented and have a significant impact on disease in adults 
as well as children. The vaccine has been estimated  to provide coverage against 88% of circulating 
serogroup B strains in England and Wales140, and was permitted for investigational use in the US in 
late 2013 and early 2014 in two outbreaks.   In September 2015 the UK Department of Health 
incorporated it into their childhood immunisation schedule. The US Food and Drugs Administration 
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have also recently approved another serogroup B vaccine for adolescents and young adults. This 
vaccine is a bivalent vaccine that utilises two families of fHbp.  
Other research priorities for the future 
New treatments to improve outcome are needed.  Research is focussed on adjunctive therapy 
targeting the host inflammatory response. Some areas of interest include matrix metalloproteinase 
(MMP) inhibitors and MRP-14 inhibitors such as paquinimod which has anti-inflammatory effects 
without affecting bacterial killing57. Inhibitors of complement and other neurotoxic mediators are 
also being investigated as well as compounds that can modulate the leukocyte response (e.g. G-
CSF)141.  
Finally, surveillance around the world remains important. The global epidemiology of bacterial 
meningitis is continually changing, especially with the introduction of new vaccines, and surveillance 
is needed to determine the breadth of coverage, monitor for serotype replacement and follow the 
emergence of new meningococcal serogroups.   Robust epidemiological studies must document 
clearly the causative agents in lower-resourced settings, especially Asia, to determine what 
vaccination strategies are necessary. Surveillance for antimicrobial resistance is also of utmost 
importance. Epidemiological research into risk factors for disease in adults and preventative 
strategies will also be important.  
Ultimately we are still some way off from the effective control of bacterial meningitis and the 
combination of a rare and deadly disease requires vigilance of the clinician, to identify and treat it in 
a timely manner, and the continued support of research partners to develop new vaccines and 
treatments. 
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